Lionel’s Newsletter | Lionel Hutz | Substack

Some non-lawyerly thoughts on the week's price action and Merck's Sotatercept trial

Mar 10

New Top Community

Today's rehearing denial from the PTAB substantially increases Liquidia's 2024 commercialization odds

Feb 2

Finally, $LQDA looks to be on the verge of commercializing a lucrative pulmonary hypertension drug

Dec 1, 2022

Who am I kidding? This won't be the last

Oct 14, 2022

And other reasons we’re all just pawns in his game

Oct 5, 2022

All week I was hoping for major updates across the 3 cases I’m currently covering, but alas, hope is not a strategy. We will have to settle for 1/3…

Sep 11, 2022

Weakness on SmartSky patent litigation and SmartSky launch news is a $GOGO buying opportunity

Sep 2, 2022

Mudge Zatko’s allegations look more like a hit piece than a real whistleblowing claim

Aug 23, 2022

Recommendations

The Chancery Daily

Chance the Lawyer

Doomberg

Monetive Wealth Market Musings

Rajaram A

Lionel’s Newsletter

About Archive Recommendations Sitemap

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts